Is Ozempic approved for weight loss?

Ozempic and Wegovy both contain semaglutide, but they carry different FDA approvals, a distinction that affects coverage, prescribing, and care.

Ozempic

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA approved it in December 2017 to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise. Its labeling also includes an indication for reducing the risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes and established cardiovascular disease. Ozempic is available in doses of 0.5 mg, 1 mg, and 2 mg, administered by weekly injection. Weight loss is a documented effect of semaglutide, but it is not what Ozempic is approved for.

Wegovy

Wegovy contains the same molecule at a higher approved maintenance dose: 2.4 mg weekly. The FDA approved it in June 2021 for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. In December 2022, that approval was extended to adolescents aged 12 and older with obesity. Wegovy is used alongside a reduced-calorie diet and increased physical activity. Weight management is its specific, formal indication, distinct from Ozempic's diabetes approval.

Side-by-side comparison

| | Ozempic | Wegovy | |---|---|---| | Active ingredient | Semaglutide | Semaglutide | | FDA indication | Type 2 diabetes management in adults | Chronic weight management in adults and adolescents (12+) | | Approved maintenance dose | Up to 2 mg weekly | 2.4 mg weekly | | FDA approval year | 2017 | 2021 (adults); 2022 (adolescents 12+) | | Intended patient population | Adults with type 2 diabetes | Adults with obesity or overweight with a weight-related condition; adolescents with obesity | | Manufacturer | Novo Nordisk | Novo Nordisk |

Several factors have fed the misconception that Ozempic and Wegovy are the same drug for the same purpose. Both contain semaglutide, so when people learn that semaglutide causes weight loss, it is a natural, if incomplete, conclusion that any product containing it is approved for that use. Ozempic also entered public awareness well before Wegovy became widely available. By the time Wegovy reached the market, Ozempic had already become cultural shorthand for GLP-1 weight-loss medications, and media coverage frequently used the two names interchangeably. Supply shortages of Wegovy kept Ozempic in the conversation further still, as some clinicians considered it when the approved product was unavailable. None of this makes interchangeable use accurate. The regulatory distinction is real and carries practical consequences, particularly for insurance coverage.

FDA approval means the agency has reviewed clinical evidence for a specific drug, at a specific dose, for a specific use, and determined that the benefits outweigh the risks for that use in the intended population. Off-label prescribing means a licensed clinician prescribes a drug for a use, dose, or patient population outside its FDA-approved labeling. This practice is legal and common across many areas of medicine. Off-label does not mean unsafe or ineffective; it means the FDA has not completed its formal review of that drug for that specific use. When Ozempic is prescribed for weight loss, that is off-label use. The underlying molecule, semaglutide, has been studied for weight management, and that evidence supported Wegovy's approval. But Ozempic itself has not been approved for that purpose. The distinction is about which product, at which dose, has gone through the formal approval process for weight management as an indication.

Off-label prescribing of Ozempic for weight loss

Off-label prescribing of Ozempic for weight loss does occur and is legal. A clinician might consider it in specific circumstances, for example when a patient has both type 2 diabetes and a need for weight management, or when Wegovy is unavailable due to supply constraints. The practical consequence that matters most to patients is coverage: insurance coverage for off-label use is not guaranteed and varies by insurer and plan. A plan that covers Wegovy for weight management may not cover Ozempic for the same purpose. Prior authorization requirements also vary. Patients should verify coverage before assuming a prescription will be paid for. The FDA does not track or publish data on how often Ozempic is prescribed off-label for weight loss, so any specific claim about the frequency of this practice would be speculation. It happens, it is legal, and its appropriateness depends on individual clinical circumstances.

If you are considering either medication for weight management, these questions are worth raising with your prescribing clinician:

Do I meet the criteria for Wegovy's approved indication? Wegovy is approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. Whether you qualify affects both clinical fit and coverage.

If Ozempic is being considered, why, and what does that mean for my coverage? Ask whether the prescription would be on-label or off-label and what that means for your insurer.

How does my insurance handle each drug? Ask specifically about prior authorization and step-therapy requirements.

What dose and titration schedule applies to my situation? Ozempic and Wegovy have different dosing regimens, and the dose matters both clinically and for coverage purposes.

Does my medical history affect which drug is appropriate? Conditions such as type 2 diabetes or cardiovascular disease may influence which medication is the right fit and which is more likely to be covered.

Coverage decisions are made at the plan level and can change. Drug availability and formulary status also shift over time. Confirm current coverage and availability with your pharmacy and insurer before filling a prescription.